Literature DB >> 7545418

Are fine-needle breast aspirates representative of the underlying solid tumour? A comparison of receptor levels, ploidy and the influence of cytokeratin gates.

I Brotherick1, B K Shenton, T W Lennard.   

Abstract

Fifty-three solid and 33 fine-needle aspirate (FNA) samples (20 paired) of human breast carcinomas were examined by flow cytometry. Experiments were conducted to assess whether FNA samples were phenotypically representative of the solid tumour. Quantification of oestrogen receptor (ER), epidermal growth factor receptor (EGFR), c-erbB-2 receptor levels and ploidy were examined on the total and cytokeratin-positive cell populations. The absolute number of molecules of cytokeratin per cell expressed on the FNA (n = 33) and solid tumour (n = 53) samples showed no significant difference, but, on a proportional basis, there was a significant difference between the two samples (P = 0.004), with lower expression exhibited by the FNAs. Examination of paired data showed no significant difference in the percentage of cytokeratin-positive cells (P = 0.51) or in the number of cytokeratin molecules expressed (P = 0.25). While the correlation for ER expression between paired tumour and FNA samples in the absence of cytokeratin gating was P = 0.06, r2 = 0.18, clear correlation was shown when a cytokeratin gate was used (P = 0.005, r2 = 0.4). Repeating this experiment for EGFR, it was found that no correlation was seen between FNA and solid tumour (P = 0.2, r2 = 0.14) in ungated populations, but use of the cytokeratin gate improved the correlation (P = 0.05, r2 = 0.3). A similar finding was seen with c-erbB-2 expression (P = 0.2, r2 = 0.1) without cytokeratin gating and when it was employed (P = 0.05, r2 = 0.4). Ploidy data showed concordance in 18/20 cases. Three cases of aneuploidy were missed by FNA, and this was because of an insufficient number of cells for analysis. The presented data suggest that FNAs are representative of solid tumours and may be useful for measuring receptor levels on clinical material when cytokeratin gating is used. However, observation by light microscopy is still necessary to confirm the presence of tumour cells in FNAs subjected to flow cytometry.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7545418      PMCID: PMC2033883          DOI: 10.1038/bjc.1995.402

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  17 in total

1.  Use of the biotinylated antibody DAKO-ER 1D5 to measure oestrogen receptor on cytokeratin positive cells obtained from primary breast cancer cells.

Authors:  I Brotherick; T W Lennard; S Cook; R Johnstone; B Angus; M P Winthereik; B K Shenton
Journal:  Cytometry       Date:  1995-05-01

2.  NCL-5D3: a new monoclonal antibody recognizing low molecular weight cytokeratins effective for immunohistochemistry using fixed paraffin-embedded tissue.

Authors:  B Angus; J Purvis; D Stock; B R Westley; A C Samson; E G Routledge; F H Carpenter; C H Horne
Journal:  J Pathol       Date:  1987-12       Impact factor: 7.996

3.  Clonal analysis and in situ characterization of lymphocytes infiltrating human breast carcinomas.

Authors:  T L Whiteside; S Miescher; J Hurlimann; L Moretta; V von Fliedner
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

4.  Flow cytometric analysis of DNA content and keratins by using CK7, CK8, CK18, CK19, and KL1 monoclonal antibodies in benign and malignant human breast tumors.

Authors:  M Ferrero; F Spyratos; V Le Doussal; A Desplaces; J Rouëssé
Journal:  Cytometry       Date:  1990

5.  Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.

Authors:  C Wright; B Angus; S Nicholson; J R Sainsbury; J Cairns; W J Gullick; P Kelly; A L Harris; C H Horne
Journal:  Cancer Res       Date:  1989-04-15       Impact factor: 12.701

6.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.

Authors:  D J Slamon; G M Clark; S G Wong; W J Levin; A Ullrich; W L McGuire
Journal:  Science       Date:  1987-01-09       Impact factor: 47.728

7.  Steroid-hormone receptors and survival after first relapse in breast cancer.

Authors:  A Howell; D M Barnes; R N Harland; J Redford; V H Bramwell; M J Wilkinson; R Swindell; D Crowther; R A Sellwood
Journal:  Lancet       Date:  1984-03-17       Impact factor: 79.321

8.  Quantitative assays of epidermal growth factor receptor in human breast cancer: cut-off points of clinical relevance.

Authors:  S Nicholson; J R Sainsbury; G K Needham; P Chambers; J R Farndon; A L Harris
Journal:  Int J Cancer       Date:  1988-07-15       Impact factor: 7.396

9.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

Review 10.  c-erbB-2 oncogene as a prognostic marker in breast cancer.

Authors:  T J Perren
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

View more
  5 in total

1.  Oestrogen and progesterone receptor assessment in core biopsy specimens of breast carcinoma.

Authors:  A Zidan; J S Christie Brown; D Peston; S Shousha
Journal:  J Clin Pathol       Date:  1997-01       Impact factor: 3.411

2.  A flow cytometric study of c-erbB-3 expression in breast cancer.

Authors:  I Brotherick; B K Shenton; B Angus; I S Waite; C H Horne; T W Lennard
Journal:  Cancer Immunol Immunother       Date:  1995-11       Impact factor: 6.968

3.  Differential p53 protein expression in breast cancer fine needle aspirates: the potential for in vivo monitoring.

Authors:  H M Ball; T R Hupp; D Ziyaie; C A Purdie; N M Kernohan; A M Thompson
Journal:  Br J Cancer       Date:  2001-10-19       Impact factor: 7.640

4.  Expression of oestrogen and progesterone receptors in gastric cancer: a flow cytometric study.

Authors:  D Karat; I Brotherick; B K Shenton; D Scott; S A Raimes; S M Griffin
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

5.  AMG 900, a potent inhibitor of aurora kinases causes pharmacodynamic changes in p-Histone H3 immunoreactivity in human tumor xenografts and proliferating mouse tissues.

Authors:  Gloria Juan; Tammy L Bush; Connie Ma; Raffi Manoukian; Grace Chung; Jennifer M Hawkins; Stephen Zoog; Richard Kendall; Robert Radinsky; Robert Loberg; Greg Friberg; Marc Payton
Journal:  J Transl Med       Date:  2014-11-04       Impact factor: 5.531

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.